Exabis Library
Welcome to the e-CCO Library!
P410 Could the disease become ‘a friend’? The mediating role of illness acceptance on self-efficacy and quality of life of gastroenterological patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P410: Extraintestinal manifestations and quality of life in patients with ulcerative colitis: 1-year data from ICONIC
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P410: Has body composition any effect on thiopurine level in IBD?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P410: Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P410: safety of biological drugs for inflammatory bowel disease in elderly patients
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P410: Segmental endoscopic scoring improves outcome prediction in acute severe colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P410: Vedolizumab is safe and effective for IBD, but has no effect on liver biochemistry in patients with concurrent PSC
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P410: Which patients with established Crohn's disease benefit most from the use of the Patency capsule test prior to small bowel capsule endoscopy?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P411 Faecal calprotectin is more tightly associated with endoscopic disease activity compared with other biomarkers in patients with inflammatory bowel disease under maintenance treatment with adalimumab
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P411: Baseline Hypertrophy of the Submucosa at intestinal ultrasound predicts Failure of Treatment in patients with ulcerative colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P411: Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease centre: Accessibility, resource utilisation and outcomes
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P411: Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P411: Early ultrasound assessment predicts therapy response: an easy tool for clinical decision making
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P411: Four-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P411: Stable pharmacokinetics and biochemical markers of inflammatory bowel disease activity: Results from a real-world adalimumab biosimilar switching program
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P411: Using wearable devices to assess pain in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P412 Maintenance therapy of vedolizumab (VDZ) after induction of remission by tacrolimus (TAC) in patients with refractory ulcerative colitis (UC)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P412: Drug persistence and endoscopic, histologic and biochemical remission rates among patients following ileal pouch-anal anastomosis treated with biologic therapy: Results from a prospective patient cohort.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P412: Effectiveness of ustekinumab in fistulising perianal Crohn´s disease refractory or intolerant to anti-TNF
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P412: Efficacy and safety of additional autologous platelet-rich stroma in transanal mucosal advancement flap repair of complex cryptoglandular anal fistulas
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM